OTC Markets OTCQB - Delayed Quote USD
Satellos Bioscience Inc. (MSCLF)
0.4670
0.0000
(0.00%)
At close: May 2 at 4:00:00 PM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Cost of Revenue
206.9370
--
--
--
119.9190
Gross Profit
-206.9370
--
--
--
-119.9190
Operating Expense
27,808
27,808
15,463
8,428
4,701.3520
Operating Income
-27,808
-27,808
-15,463
-8,428
-4,701.3520
Net Non Operating Interest Income Expense
1,371
1,371
1,156
63
-977.3460
Other Income Expense
-1,662
-1,662
-1,582
-2,952
-9,826.9540
Pretax Income
-28,099
-28,099
-15,889
-11,317
-15,505.6520
Tax Provision
--
--
--
5
--
Net Income Common Stockholders
-28,099
-28,099
-15,889
-11,322
-15,505.6520
Diluted NI Available to Com Stockholders
-28,099
-28,099
-15,889
-11,322
-15,505.6520
Basic EPS
0.25
0.25
-0.18
-0.32
-0.64
Diluted EPS
0.25
0.25
-0.18
-0.32
-0.64
Basic Average Shares
114,778.3510
114,778.3510
86,404.7620
35,680.1130
24,076.4570
Diluted Average Shares
165,819.8720
114,778.3510
86,404.7620
35,680.1130
24,076.4570
Total Operating Income as Reported
-27,808
-27,808
-15,463
-8,428
--
Total Expenses
27,808
27,808
15,463
8,428
4,701.3520
Net Income from Continuing & Discontinued Operation
-28,099
-28,099
-15,889
-11,322
-15,505.6520
Normalized Income
-26,437
-26,437
-14,307
-9,143.7192
-5,722.5390
Interest Income
1,371
1,371
1,333
63
7.9860
Interest Expense
--
--
177
--
985.3320
Net Interest Income
1,371
1,371
1,156
63
-977.3460
EBIT
-28,099
-28,099
-15,712
-11,317
-14,520.3200
EBITDA
-28,079
-28,079
-15,705
-10,980
-14,354.6350
Reconciled Cost of Revenue
206.9370
--
--
--
119.9190
Reconciled Depreciation
20
20
7
337
165.6850
Net Income from Continuing Operation Net Minority Interest
-28,099
-28,099
-15,889
-11,322
-15,505.6520
Total Unusual Items Excluding Goodwill
-1,662
-1,662
-1,582
-2,952
-9,783.1130
Total Unusual Items
-1,662
-1,662
-1,582
-2,952
-9,783.1130
Normalized EBITDA
-26,417
-26,417
-14,123
-8,028
-4,571.5220
Tax Rate for Calcs
--
--
--
0.0003
--
Tax Effect of Unusual Items
--
--
--
-773.7192
--
12/31/2021 - 8/3/2012
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
MDNAF Medicenna Therapeutics Corp.
0.7870
+0.03%
NGENF NervGen Pharma Corp.
2.5300
+12.44%
SNPX Synaptogenix, Inc.
2.4200
-5.10%
NYMXF Nymox Pharmaceutical Corporation
0.0903
0.00%
ELTX Elicio Therapeutics, Inc.
5.50
+9.56%
BCT.TO BriaCell Therapeutics Corp.
5.62
-1.40%
RZLT Rezolute, Inc.
4.0000
+1.01%
CTNM Contineum Therapeutics, Inc.
4.1000
+3.27%
XENE Xenon Pharmaceuticals Inc.
38.28
+0.50%
EWTX Edgewise Therapeutics, Inc.
16.91
+1.38%